TransMedics Group (TMDX) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $114.3 million, up 118% year-over-year, with net income of $12.2 million and positive free cash flow for the first time.

• Growth driven by increased OCS adoption, NOP expansion, and logistics network momentum, with nearly all U.S. customers participating.

• Gross margin declined to 61% from 70% in Q2 2023 due to a higher mix of service revenue.

• Operating expenses rose to $56.8 million, reflecting R&D and SG&A expansion.

• Cash reserves increased to $362.8 million as of June 30, 2024.

Financial highlights

• Q2 2024 revenue: $114.3 million, up from $52.5 million in Q2 2023; U.S. transplant revenue was $108.5 million, ex-U.S. revenue $4.7 million.

• Net income for Q2 2024: $12.2 million (10.7% of revenue); diluted EPS: $0.35.

• Gross margin: 61% overall; product gross margin 80%, service margin 28%.

• Operating expenses: $56.8 million, up from $37.6 million in Q2 2023.

• Cash balance: $362.8 million as of June 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $425–$445 million, representing 76%–84% growth over 2023.

• Guidance factors in scheduled aircraft maintenance, OUS revenue variability, and continued NOP and OCS adoption.

• Gross margins projected to improve over the next 12–18 months; operating expenses to grow at a slower rate.

• Existing cash expected to fund operations, capex, and debt service for at least 12 months.

• Plans to launch new OCS lung and heart clinical programs in 2025.